Anzeige
Mehr »
Login
Donnerstag, 29.02.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
InnoCan Pharma: Jetzt der Ausbruch aus dem Faultierkäfig?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 886715 | ISIN: US0463531089 | Ticker-Symbol: ZEGA
Siehe auch ASTRAZENECA PLC
Tradegate
29.02.24
21:31 Uhr
59,00 Euro
-1,50
-2,48 %
1-Jahres-Chart
ASTRAZENECA PLC ADR Chart 1 Jahr
5-Tage-Chart
ASTRAZENECA PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
59,0059,5022:33
59,0059,5022:00

Aktuelle News zur ASTRAZENECA PLC ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:10Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK6
MiICR study reveals AstraZeneca's ceralasertib sensitises tumours to immunotherapy6
DiAstraZeneca finally drops roxadustat US rights after FDA rejection, trial failure3
DiAstraZeneca's Voydeya receives CHMP recommendation for rare blood disease PNH3
DiEMA CHMP recommends AstraZeneca's Voydeya for PNH treatment4
DiAstraZeneca makes Shanghai its fifth global strategic hub14
MoFibroGen regains rights to anemia drug from AstraZeneca10
MoAstraZeneca returns right to roxadustat to FibroGen11
MoFibroGen, Inc.: FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea104The FibroGen - AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc....
► Artikel lesen
MoSilence Therapeutics: $10 Million Milestone Payment Achieved From AstraZeneca11
MoAlexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign11
MoAstraZeneca's Tagrisso shows promise as lung cancer maintenance therapy12
MoAstraZeneca gets EU backing for blood disorder add-on therapy4
MoAstraZeneca's Voydeya treatment recommended for EU approval4
MoAstraZeneca's blood-disorder drug recommended for EU approval2
MoAstraZeneca: Voydeya Recommended For Approval In The EU By CHMP277LONDON (dpa-AFX) - AstraZeneca PLC (AZN.L, AZN) announced Voydeya has been recommended for marketing authorisation in the European Union as an add-on to ravulizumab or eculizumab for the treatment...
► Artikel lesen
MoAstraZeneca PLC: Voydeya recommended for EU approval12926 February 2024 Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia Recommendation of...
► Artikel lesen
FrPhase 3 data for AstraZeneca's Fasenra published in NEJM5
FrAstraZeneca Acquires Gracell Biotechnologies4
FrSilence Therapeutics receives $10M payment from AstraZeneca collaboration3
Seite:  Weiter >>
831 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1